Table of Contents Table of Contents
Previous Page  247 / 916 Next Page
Show Menu
Previous Page 247 / 916 Next Page
Page Background

25th European Congress of Psychiatry / European Psychiatry 41S (2017) S238–S302



There is a statistically significant cognitive decline in

patients with mild and moderate depression.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.


Emotional schemas: A new cognitive

perspective for the distinction

between unipolar depression and

bipolar disorder

O. Onur

Istanbul Bakırköy Research and Training Hospital for psychiatry

neurology and ne, Psychiatry, Istanbul, Turkey


Clinicians need to make the differential diagnosis

between unipolar depression and bipolar disorder to guide their

treatment choices. Looking at the differences observed in the emo-

tional schemas might help with this differentiation. This study is

an exploratory investigation of schema theory’s Leahy’s emotional

schemas among individuals diagnosed with bipolar disorder and

unipolar depression.


Three groups of subjects 56 unipolar depression in the

remission period, 70 bipolar eutimic and 58 healthy controls were

asked to fill out the Leahy Emotional Schema Scale (LESS). The

clinicians diagnosed the participants according to the criteria of

DSM-IV-TR with SCID-I, and rated the moods of the subjects with

the Beck Depression Scale, and the Young Mania Rating Scale

(YMRS). Statistical analyses were undertaken to identify the group

differences on LESS.


The bipolar eutimic and unipolar depression patients’

scores on the LESS dimensions were significantly different from the

healthy participants in the areas of control, consensus, acceptance

of feelings, dissimilarity and simplistic view of emotions.


These results suggest that the metacognitive model

of unipolar depression might be extrapolated for patients with

bipolar disorder. Bipolar disorder may be associated with a general

activation of the emotional schemas.

Disclosure of interest

The author has not supplied his/her decla-

ration of competing interest.


Anxiety, stress and depression on

COPD patients. A qualitative research

E. Kotrotsiou

1 ,

, E. Tzounis


, Z. Daniil


, C. Hatzoglou



N. Skenteris


, K. Gourgoulianis



University of Applied Sciences of Thessaly, Nursing, Postgraduate

Program in Primary Health Care, Laboratory Science of Care, Larissa,



Primary National Health Network, Health Unit, Volos, Greece


University of Thessaly, Medicine, Larissa, Greece


University of Thessaly, Medicine, Postgraduate Program of Primary

Health Care, Larissa, Greece

Corresponding author.


COPD is a common disease, has an impact not only

on psychical but also on psychological well-being. Anxiety, stress,

depression are common co-morbidities for COPD patients.


This paper proposes to study from a qualitative point

of view the effect of depression on COPD patients.


A qualitative methodology was chosen in order to explore

75 (male


= 69, female


= 6) COPD patients’ symptoms and signs

of anxiety, stress and depression.


Data were collected through semi-structured inter-

views. All patients also completed the Beck Inventory and the GDS

15 questionnaires. The interviews were conducted both in the gen-

eral university hospital of Larissa and in patients’ homes.


We enrolled 75 patients (15: normal, 17: mild depres-

sion, 7: moderate and 1 severe). Persistent low mood and lack

of interest was expressed by most of the participants. “Before I

get this thing, I was in a good mood, but not now”. Poor self-

management was associated with anxiety disorders and high

temper: “I withdrew, due to my health”

. . .

“I was really stressed,

and depressed, and quick-tempered”. COPD diagnosis was diffi-

cult for some patients: “At the beginning, I wasn’t in the mood for

anything, just sleeping and more of watching TV”. Other patients

seemed to be in a good mood: “I was never scared of anything, I am



This research shows that depressive and anxiety

symptoms are common among COPD patients. Depression has a

significant impact on the daily life of patients while breathlessness

made patients feel housebound and social isolated.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.


Lurasidone for the treatment of major

depressive disorder with mixed

features: Do manic symptoms

moderate treatment response?

A. Pikalov

1 ,

, J. Goldberg


, Y. Mao


, C. Siu


, J. Tsai



J. Calabrese


, A. Loebel



Sunovion Pharmaceuticals Inc., Global Medical Affairs, Fort Lee, USA


Icahn School of Medicine at Mount Sinai, Psychiatry, NY, USA


Sunovion Pharmaceuticals Inc., Medial Affairs, Fort Lee, USA


COS and Associates Ltd., Data Science, Hong Kong S.A.R.


UH Case Medical Center, Psychiatry, Cleveland, USA

Corresponding author.


This post-hoc analysis evaluated whether the effi-

cacy of lurasidone in major depressive disorder (MDD) with mixed

features is moderated by the number and characteristics of manic

symptoms present at study baseline.


Patients meeting DSM-IV-TR criteria for MDD who

presented with two or three manic symptoms (consistent with

the DSM–5 mixed features specifier) were randomly assigned

to 6 weeks of double-blind treatment with either lurasidone

20–60mg/d (


= 109) or placebo (


= 100). Finite mixture models

were applied to identify latent class patterns of the 10 baseline

manic symptoms.


Three latent class profiles were identified: 105 (50.5%)

patients had manic symptom profile 1 (MIX 1) with mean MADRS

33.0, mean YMRS 9.2, mean number of manic symptoms 3.8; 63

(30.3%) patients had manic symptom profile 2 (MIX 2) with similar

baseline mean MADRS (32.4) and YMRS (9.3) and lower number

of manic symptoms 3.5; 40 patients had manic symptom profile

3 (MIX 3) with significantly higher severity scores in MADRS (35)

and YMRS (14.9) and mean number of manic symptoms 4.6. A sig-

nificant moderating effect on change in YMRS score was observed

for the “decreased need for sleep” symptom, with greater lurasi-

done effect size (vs. Placebo) found in patients without vs. With

this symptom (


< 0.05).


In this post-hoc analysis of a placebo-controlled trial

involvingMDDpatientswithmixed features, absence of “decreased

need for sleep” was found to be significantly associated with

improvement in manic and depressive symptoms and to moderate

the treatment effect on manic symptoms.

Disclosure of interest

I am full time employee of Sunovion phar-

maceuticals Inc.